Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5185774 | 0.87 | TSHR (0.59) | TSHRMAPK1 | |
| SCHEMBL5029019 | 0.87 | TSHR (0.59) | TSHRMAPK1 | |
| SCHEMBL8897375 | 0.83 | TSHR (0.43) | TSHRALDH1A1MEN1CYP3A4ALOX15 | |
| SCHEMBL5187460 | 0.80 | TSHR (0.46) | TSHR | |
| SCHEMBL10026572 | 0.80 | MEN1 (0.33) | TSHRALDH1A1MEN1CYP3A4ALOX15 | |
| SCHEMBL18471527 | 0.78 | TSHR (0.32) | TSHRALDH1A1 | |
| SCHEMBL5127678 | 0.75 | TSHR (0.53) | TSHR | |
| SCHEMBL7522855 | 0.74 | CETP (0.43) | ALDH1A1KMT2A | |
| SCHEMBL7522606 | 0.74 | CETP (0.43) | ALDH1A1KMT2A | |
| SCHEMBL7532833 | 0.74 | CETP (0.43) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2024-06-27 | — | — | US | disclosed |
| WO-2024112894-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20180035705-A1 | COMPOSITIONS PROVIDING EXTENDED ENERGY AND METHODS OF USE | BLUE DRAGONFLY, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20170080037-A1 | Compositions for Regulation and Control of Appetite | Therapeutic Solutions LLC | 2017-03-23 | — | — | US | disclosed |
| US-20120196817-A1 | METHOD FOR ENHANCING NUTRIENT ABSORPTION WITH ASTRAGALOSIDES | NULIV HOLDING INC. (TW) | 2012-08-02 | — | — | US | disclosed |
| US-20120196816-A1 | METHOD FOR ENHANCING NUTRIENT ABSORPTION WITH ASTRAGALOSIDES | NULIV HOLDING INC. (TW) | 2012-08-02 | — | — | US | disclosed |
| US-8197860-B2 | Method for enhancing nutrient absorption with astragalosides | NULIV HOLDING INC. (TW) | 2012-06-12 | — | — | US | disclosed |
| US-8168596-B2 | Use of cycloartane compounds for treating arthritis | NULIV HOLDING INC. (TW) | 2012-05-01 | — | — | US | disclosed |
| US-7959952-B2 | topical administration of water insoluble extracts from Astragalus membranaceus comprising cycloartane or astragaloside compounds, to improve skin texture, reducing wrinkles, for ultraviolet radiation protection and antiaging effects | NULIV HOLDING INC. (TW) | 2011-06-14 | — | — | US | disclosed |
| US-20100099633-A1 | METHOD FOR ENHANCING NUTRIENT ABSORPTION WITH ASTRAGALOSIDES | NULIV HOLDING INC. (TW) | 2010-04-22 | — | — | US | disclosed |
| US-20100099637-A1 | USE OF CYCLOARTANE COMPOUNDS FOR TREATING ARTHRITIS | NULIV HOLDING INC. (TW) | 2010-04-22 | — | — | US | disclosed |
| US-20080057010-A1 | METHOD FOR SKIN CARE | NULIV SCIENCE LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099637-A1 | USE OF CYCLOARTANE COMPOUNDS FOR TREATING ARTHRITIS | COL2A1, COL1A1, COL14A1 | TSHR 2632/4885ALDH1A1 1457/4885MAPK1 2067/4885 |
| US-20100099633-A1 | METHOD FOR ENHANCING NUTRIENT ABSORPTION WITH ASTRAGALOSIDES | FABP2, SI, SLC10A2 | TSHR 1885/4885ALDH1A1 1984/4885MAPK1 3965/4885 |
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | TSHR 4140/4885ALDH1A1 4776/4885MAPK1 1701/4885 |
| US-20170080037-A1 | Compositions for Regulation and Control of Appetite | FABP6, TAS2R60, TAS2R40 | TSHR 449/4885ALDH1A1 4462/4885MAPK1 2097/4885 |
| US-20120196817-A1 | METHOD FOR ENHANCING NUTRIENT ABSORPTION WITH ASTRAGALOSIDES | FABP2, SI, SLC10A2 | TSHR 1885/4885ALDH1A1 1984/4885MAPK1 3965/4885 |
| US-20080057010-A1 | METHOD FOR SKIN CARE | CUTA, GLA, BCAS2 | TSHR 4017/4885ALDH1A1 2902/4885MAPK1 3067/4885 |
| US-20120196816-A1 | METHOD FOR ENHANCING NUTRIENT ABSORPTION WITH ASTRAGALOSIDES | FABP2, SI, SLC10A2 | TSHR 1885/4885ALDH1A1 1984/4885MAPK1 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.